Preliminary List of Invited Speaker Presentation Titles
(arranged alphabetically according to invited speaker)
Updated 2 August, 2016

TBA
Enrico Agabiti-Rosei, Dept. of Medical and Surgical Sciences, University of Brescia, Italy

TBA
Giuseppe Ambrosio, Dept. of Cardiology, University of Perugia School of Medicine, Perugia, Italy

PCSK9: Together or Alone? Current State of Knowledge 2017
Maciej Banach, Dept. of Hypertension, Medical University of Lodz, Poland

From Epidemiological Transition to Modern Cardiovascular Epidemiology: Hypertension in the 21st Century
Jacques Blacher, Hypertension and cardiovascular prevention unit, Hôtel-Dieu university Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Descartes, Paris, France

Total Cardiovascular Risk Evaluation and Management in patients with PAD
Marianne Brodmann, Dept. of Internal Medicine, Medical University Graz, Austria

Need for Pleitropic Therapy in Chronic Heart Failure
Dirk L. Brutsaert, Professor-Emeritus, University of Antwerp, Antwerp, Belgium

TBA
Francesco Cosentino, Cardiology Unit, Dept. of Medicine, Karolinska University Hospital, Solna, Sweden

Bariatric Surgery and Cardio Metabolic Risk Factors Control
Sébastien Czernichow, Dept. of Nutrition, Assistance Publique-Hôpitaux de Paris, Hôpital A Paré, Université Versailles St-Quentin, Boulogne, France

TBA
Wolfram Doehner, Dept. of Cardiology, Center for Stroke Research Berlin – CSB, Berlin, Germany

Amiloride, an Obligatory Companion of Chlorthalidone and other Diuretics
Flávio D. Fuchs, Hospital de Clinicas de Porto Alegre, Brazil

TBA
Dov Gavish, Medicine A Wolfson, Sackler Faculty of Medicine Tel Aviv University, Israel

TBA
Guido Grassi, Dept of Internal Medicine, University of Milano Biocca, Milan, Italy

Which Combination Therapy in the Renal Patient?
Jean-Michel Halimi, Service de Néphrologie-Immunologie Clinique, Hôpital Bretonneau, Tours cedex, France

Inhibition of SGLT-2 and Antihypertensive Treatment Strategies: New Mechanisms of Cardiovascular Protection
Hermann Haller, Dept. of Nephrology and Hypertension Medicine, University of Hannover, Hannover Medical School, Germany

Selecting Best Fixed Combination by Personal Genetic Risk Score
Pavel Hamet, University of Montreal and Dept. of Experimental Medicine at McGill University, Canada

TBA
Dror Harats,

Fixed Combination of GLP-1 Receptor Agonists and Insulin: An Approach to Increased Effectiveness with Improved Tolerability?
Phillip Home, Diabetes Medicine, Newcastle University, UK

TBA
Mohsen Ibrahim, Dept. of Cardiology, University of Cairo, Egypt

Novel Combination Therapy in Hypertension: Chlorthalidone with Spironolactone
Uday Jadhav, Dept. of Cardiology, MGM New Bombay Hospital, Vashi, India

What is the Optimal Two-Drug and Three-Drug Fixed Combination?
Andrzej Januszewicz, Dept. of Hypertension, Institute of Cardiology, Warsaw, Poland

TBA
Bojan Jelakovic, University of Zagreb School of Medicine, University Hospital Center Zagreb, Croatia

Combination Antihypertensive Therapy in Chronic Kidney Disease: Does SPRINT Tell us the Truth?
Alexander Kirsch, Medical University Graz, Department of Internal Medicine,
Clinical Division of Nephrology, Graz, Austria

Arterial Destiffening in Hypertensive Patients with Type 2 Diabetes
Stephane Laurent, Dept. of Clinical Pharmacology in the Hôpital Européen Georges Pompidou, France

Why and How do We Have to Use Drugs Combinations for Treatment of Hypertensive Patients
Bernard I. Levy, Emeritus Professor of Physiology, France

TBA
Basil S. Lewis, Lady Davis Carmel Medical Center, The Ruth and Bruce Rappaport School of Medicine of the Technion, Haifa, Israel

Long Term Advantages of Initial Combination Treatment: New Evidence
Giuseppe Mancia, University of Milano Bicocca, Milano, Italy

TBA
Dimitri Mikhailidis, University College London, UK

Combination Therapy in the Hypertensive Patient with Coronary Artery Disease
Paolo Palatini, Dept. of Medicine, Vascular Medicine, University of Padova, Italy

TBA
Gianfranco Parati, Cardiology Unit, Istituto Auxologica Italiano, Milan and Dept. of Health Sciences, Universita di Milano-Bicocca, Milan, Italy

TBA
Atul Pathak, Cardiologie / Pharmacologie, Clinique Pasteur, INSERM 1048, Centre de Recherche Clinique Cardiovasculaire Pasteur / CHU, France

Combination Therapies in Diabetes from Recherché to Guidelines
Itamar Raz, Dept. of Medicine, Hadassah University Hospital, Ein-Karem, Jerusalem, Israel

Cross-Talk between Microcirculation and Macrocirculation: Effects of Combination Treatment
Damiano Rizzoni, Dept. of Medical and Surgical Sciences, University of Brescia, Italy

Combination Antihypertensive Therapy in Chronic Kidney Disease: Does SPRINT Tell us the Truth?
Alexander R. Rosenkranz, Medical University Graz, Department of Internal Medicine, Clinical Division of Nephrology, Graz, Austria

Can a Polypill, One Single Tablet, Combat Different Cardiovascular Risk Factors?
Talma Rosenthal, Sackler Faculty of Medicine, Tel Aviv University, Israel

Criticial Evaluation of Different Antidiabetic Fix-Dose Combination Therapies for Type 2 Diabetes
Guntram Schernthaner, Dept. of Medicine I, Rudolfstiftung Hospital, Vienna, Austria

Impact of Fixed-Dose Antihypertensive Treatment on Target-Organ Damage
Giuseppe Schillaci, Dept. of Medicine and Unit of Internal Medicine Terni University Hospital, Italy

Fixed Dose Combinations with Empagliflozin
Eberhard Standl, Munich Diabetes Research Group e.V. at Helmholtz Centre, Munich, Germany

Correct Combinations of Antihypertensive Drugs According to the Principles of Clinical Pharmacology
Stefano Taddei, Dept. of Clinical and Experimental Medicine, University of Pisa, Italy

Vascular Biology of Hypertension: Clinical Implications
Rhian M. Touyz, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK

Why using a Polypill in Patients at High Cardiovascular risk? Are we not Polypilling Anyway?
Thomas Unger, CARIM – School for Cardiovascular Diseases, Maastricht University

Benefits and Burdens of Antihypertensive Treatment: Meta-Analyses of Randomized Controlled Trials
Alberto Zanchetti, Emeritus Professor of Internal Medicine at the University of Milan, Italy

TBA
Yuqing Zhang, Division of Hypertension, Fu Wai Hospita, Beijing, China

Combination Therapy in the Cardiometabolic Syndrome: Past, Present and Future
Reuven Zimlichman, Sackler Faculty of Medicine, Tel Aviv University, The E. Wolfson Medical Center, Holon, Israel